Clinical Trial Search

Primary: Trough Forced Expiratory Volume in One Second (FEV1) Response After 24 Weeks — -0.034; 0.044; 0.066; 0.087 litre

Primary: Overall Survival (OS) — 12.88; 8.97 months — p=0.00142

Primary: Change From Baseline of Weekly Urticaria Activity Score (UAS7) at Week 24 — -20.36; -22.50; -21.26 Score on a scale

Primary: Rate of Binge Eating Episodes [Binge Eating Sample Only] — 0.256; 0.210; 0.219; 0.205 binge eating episodes

Primary: Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up — 2.32; 1.96 units on a scale

Primary: Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group — 0.38; 0.45; 0.76; 0.73 proportion

Primary: Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle…

Primary: Change From Baseline in Ocular Surface Staining — 1.2; 2.4 score on a scale

Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale

Primary: Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC — 15.6; 5.12 events/hour

Primary: Mean Within-Treatment Whole-Mouth Score - Gingival Efficacy — 2.081; 2.094; 2.092; 1.996 units on a scale

Primary: Grip Strength — 17.8; 23.4; 24.7; 25 kg

Primary: Change From Baseline in Total Lesion Count at Week 12 — -10.2; -12.0 number of lesions — p=0.366

Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 47.5; 37.6; 38.8; 43.0 Percentage of Participants — p== 0.525

Primary: Objective Response Rate (ORR) — 13.8 percentage of participants